eliglustat + digoxin

Eliglustat is an oral small molecule inhibitor of glucosylceramide synthase used as a substrate reduction therapy for the long-term treatment of type 1 Gaucher disease in adults who are CYP2D6 extensive, intermediate, or poor metabolizers. It works by inhibiting UDP-glucosylceramide synthase (also known as glucosylceramide synthase), thereby reducing the synthesis and accumulation of glucosylceramide in lysosomes[3][6][8]. Digoxin is a cardiac glycoside used to treat mild to moderate heart failure and to control ventricular response rate in chronic atrial fibrillation. Its primary mechanism is reversible inhibition of Na-K ATPase (sodium-potassium pump), leading to increased intracellular sodium and calcium concentrations in myocardial cells and enhanced contractility[2]. When coadministered, eliglustat increases exposure to digoxin due to its effect on P-glycoprotein-mediated transport; dose adjustments may be required for digoxin when given with eliglustat[1][7].

Other names

eliglustat tartratecardiac glycoside